DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ncgfns/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H2 2012" report to their offering.
'Perennial Allergic Rhinitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Perennial Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis.
Scope
- A snapshot of the global therapeutic scenario for Perennial Allergic Rhinitis.
- A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Perennial Allergic Rhinitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Involved in Perennial Allergic Rhinitis Therapeutics Development
- Shionogi & Co., Ltd.
- GlaxoSmithKline plc
- Nycomed International Management GmbH
- Sun Pharmaceutical Industries Limited
- GenMont Biotech Inc.
- VentiRx Pharmaceuticals, Inc.
- Adamis Pharmaceuticals Corporation
Drug Profiles
- ciclesonide
- VTX-1463
- S-555739
- fluticasone furoate
- Modified Allergen Extract
- GMNL-32
- SUN-1334 H
- SUN-1334 H
- TBS-6
- APC-3000
For more information visit http://www.researchandmarkets.com/research/ncgfns/perennial
